ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Biogen Inc

Biogen Inc (1BIIB)

155.15
3.15
(2.07%)
마감 04 12월 1:30AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
155.15
매수가
153.00
매도가
155.15
거래량
46
154.00 일간 변동폭 155.25
146.95 52주 범위 244.60
market_cap
전일 종가
152.00
개장가
155.25
최근 거래 시간
16
@
155.15
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
45
발행 주식
145,719,340
배당수익률
-
주가수익률
20.43
주당순이익(EPS)
7.97
매출
9.84B
순이익
1.16B

Biogen Inc 정보

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the 이탈리아 증권거래소 with ticker 1BIIB. The last closing price for Biogen was 152.00 €. Over the last year, Biogen shares have traded in a share price range of 146.95 € to 244.60 €.

Biogen currently has 145,719,340 shares in issue. The market capitalisation of Biogen is 22.15 € billion. Biogen has a price to earnings ratio (PE ratio) of 20.43.

1BIIB 최신 뉴스

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 The detailed study results confirmed interim...

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB...

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study...

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients Designation is based on data from the...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
15.253.50233488993149.9155.25149.926151.69873418DE
4-13.2-7.84080784081168.35168.35146.9533157.13221709DE
12-24.7-13.7336669447179.85182146.9545167.77678959DE
26-51.85-25.0483091787207220.7146.9539180.6355321DE
52-60.45-28.0380333952215.6244.6146.9533192.38794181DE
156-60.45-28.0380333952215.6244.6146.9533192.38794181DE
260-60.45-28.0380333952215.6244.6146.9533192.38794181DE

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TALEAATalea Group AA
0.0248 €
(44.19%)
1.6M
WGIS26Gismondi 1754 SpA
0.1042 €
(29.76%)
401
WOSA25OSAI Automation System SpA
0.3289 €
(21.86%)
250
DOVAADovalue AA
1.60 €
(19.23%)
603.85k
FDAFidia
0.09 €
(14.80%)
5.37M
WISC24Integrated System Credit Consulting Fintech Spa
0.0002 €
(-93.33%)
56k
EPHEPH SpA
0.53 €
(-41.76%)
8.36k
WTFINTrevi Finanziaria Industriale Spa
0.9925 €
(-22.46%)
80
OSAOSAI Automation System SpA
0.66 €
(-14.29%)
91.24k
NTWNetweek SpA
0.011 €
(-14.06%)
675.33k
TITTelecom Italia SpA
0.2239 €
(0.13%)
119.9M
ISPIntesa Sanpaolo Spa
3.6925 €
(1.67%)
55.37M
SPMSaipem Spa
2.506 €
(2.92%)
49.46M
ENELEnel Spa
6.925 €
(1.38%)
29.79M
STLAMStellantis NV
11.968 €
(1.89%)
20.86M
trucker20 trucker20 5 분 전
There are 4 different companies who have posted the same post.
BBUZ
wooferwax wooferwax 5 분 전
you should probably wait until they are bringing in massive profits. Of course you will be paying dollar bills by then, but all means wait it out.
IQST
glenn1919 glenn1919 5 분 전
CTMX.....CHRS......CTOR.....SOAR.......https://stockcharts.com/h-sc/ui?s=SOAR&p=D&yr=0&mn=2&dy=12&id=p84071410134
CHRS CTMX CTOR
ssc ssc 6 분 전
Agree. How about your "speculation" claiming eez block 4 drilling results and erhe dividend announcement in March 2025? Walk it back now or wait until closer to March to try and squirm out of it?
ERHE
nyt nyt 6 분 전
That's because Vplm is in its best position, ever! (for falling prices, that is...)

It's enough to make you "anti-trust" them..

They look good in double zeroes. They wear them well! They'll be stunning in trips!

They are now well past the 30 day mark for
VPLM
Golfbum22 Golfbum22 6 분 전
Why does he have any say in his opinion about the gse’s?

Has he ever been right?

Is anyone debating him from a smarter
Perspective?

Or is it just paid for hire fake news from him like the past 16 years?

He is so negative for a reason
FNMA
Techroemancer Techroemancer 6 분 전
Thank you for your due diligence. I am backing out of this while the going is good. I'm content with my gains and my risk tolerance has peaked. GLTUA and may RDAR bless your accounts as much as possible. Time to reinvest the profit into my main play.
RDAR
delerious1 delerious1 6 분 전
HFT flippers like things nice and tight with large volume...once we get the news that we've been anticipating the HFT's should back off and let er rip
NBRI
jimr1717 jimr1717 6 분 전
Lawncare worker dead after being hit by out-of-control car.

https://www.news4jax.com/news/local/2024/11/06/lawncare-worker-dead-after-being-hit-by-out-of-control-car/
TSLA
dreamaker56 dreamaker56 6 분 전
Dave is a POS. I actually signed up to X just so I can read his BS. Again, he iss publically calling out people with childish remarks just because they hold his feet to the fire. He's always got some excuse to his downfalls. Instead of admitting it he points blame everywhere else.

BLEG
JRoon71 JRoon71 6 분 전
Chrome, yes, that was my exact thought. Either they didn't have enough time for a thoughtful submission, or maybe didn't even submit at all.

We will know in subsequent communications from Amarin if their message is still that Edding is advancing efforts for reimbursement. 
AMRN
Echo115 Echo115 7 분 전
TriCascade has lots of new IoT devices that companies like Microsoft wants..
Buyout looming??
SRMX
gp22 gp22 7 분 전
AI DRONE: Nano-floater $MTEK expanding AI operations into USA...Link:

$MTEK is the low float AI Drone play yet to catch fire...Float is 4.2M w/42% of entire Share Count controlled by the CEO.

At some point it rips big.

Link:
https://www.maris-tech.
MTEK
Trooperstocks Trooperstocks 7 분 전
$ILLR Triller is crafting the future of fun by fusing multiple revenue streams into one powerhouse. Imagine an entertainment platform that's not just groundbreaking but game-changing!
ILLR
bar1080 bar1080 7 분 전
I'm sticking with my estimate that Hindenburg has been right about 85% of the time since they began in 2017. I can only recall Hindenburg being significantly off base once which was their errant short call a few years ago on American Tower (AMT), a NYSE REIT. That's an incredible record given the st
m0n m0n 7 분 전
Why so quiet here when this company has game changing technology LoL

Game changing this and Game Changing that LoL

Oh and the Joint Venture with a company that no longer exists and a consortium no one knows who they are LoL
IFUS
chklingon chklingon 7 분 전
Fair enough. I needed to take out profits. I will be back in.....
JASMYUSD
i_like_bb_stock i_like_bb_stock 7 분 전
$PTPI took a starter, overdue for news, expecting a decision on drug to go RX to otc https://x.com/thommic/status/1864002099802948051
PTPI
jimr1717 jimr1717 7 분 전
Dec 3 2024 Deputies in Illinois this week saved a pregnant woman who called 911 for help after she lost control of the vehicle she was driving and was approaching a lake.
TSLA
ETG58 ETG58 7 분 전
SGW, hate to sound like an ihub(chatroom) rookie but what is an IBOX?
I really do not know.
MONI
i_like_bb_stock i_like_bb_stock 8 분 전
$PTPI took a starter, overdue for news, expecting a decision on drug to go RX to otc https://x.com/thommic/status/1864002099802948051
PTPI
glenn1919 glenn1919 8 분 전
GWAV...........................https://stockcharts.com/h-sc/ui?s=GWAV&p=W&b=5&g=0&id=p86431144783
GWAV
Gizzer211 Gizzer211 8 분 전
Four companies?  Are they listed somewhere on X?
BBUZ

최근 히스토리

Delayed Upgrade Clock